Welcome to our dedicated page for Q/C Technologies SEC filings (Ticker: QCLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q/C Technologies, Inc. (QCLS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents give detailed insight into how Q/C describes its quantum-class, high-performance computing infrastructure business, its licensing agreement with LightSolver for quantum-inspired laser-based processing units, and its focus on applications in the crypto and blockchain domain.
Through Q/C’s Forms 10-K and 10-Q (when filed), investors can review management’s discussion of operations, risk factors, and financial statements related to its quantum-class photonic computing initiatives and related activities. The company’s Current Reports on Form 8-K disclose material events such as private placements of preferred stock and warrants, amendments to transaction documents, consulting agreements, equity incentive plan changes, and stockholder approvals for reverse stock split authorization and share issuance proposals.
Proxy statements on Schedule 14A outline matters submitted to stockholders, including proposals tied to the issuance of common stock underlying preferred stock and warrants, increases in shares available under the 2021 Equity Incentive Plan, and other governance items. Filings such as Form 12b-25 (Notification of Late Filing) explain any reported delays in submitting periodic reports and the company’s stated plans to file within allowed extension periods.
On Stock Titan, these filings are supplemented with AI-powered summaries that aim to clarify key points from lengthy documents, such as the implications of preferred stock terms, voting rights, equity plan amendments, and reverse stock split proposals. Users can also monitor ownership and compensation-related disclosures contained in proxy materials and other filings, as well as any reported unregistered sales of equity securities and warrant issuances. Real-time updates from EDGAR combined with AI explanations help readers navigate Q/C Technologies’ regulatory history and understand the structural aspects of its quantum-class computing business as presented in its official filings.
Q/C Technologies, Inc. has filed a shelf registration statement on Form S-3 to offer and sell, from time to time, up to $100,000,000 of common stock, preferred stock, debt securities, warrants, subscription rights, and units.
The company has shifted its strategy from developing Isomyosamine and Supera-CBD therapeutics to building energy‑efficient blockchain and cryptocurrency infrastructure using laser-based computing under an exclusive global license with LightSolver. The filing notes going concern risks, potential future equity dilution, Nasdaq listing compliance risks, and a high level of investment risk.
Q/C Technologies director Chelsea Sierra Voss reported new equity awards. On January 16, 2026, she received 212,500 shares of common stock as restricted stock units under a consulting agreement and 25,000 additional RSU shares tied to her appointment to the board. Both RSU grants vest in four equal quarterly installments if she continues providing services.
She also received an employee stock option for 212,500 shares of common stock at an exercise price of $5.097 per share, vesting quarterly on the same schedule. Following these awards, she beneficially owns 239,900 shares of common stock directly and 59,802 shares indirectly through a Roth IRA, plus 212,500 stock options.
Q/C Technologies, Inc. director Chelsea Sierra Voss reported her initial ownership of the company’s common stock as of 01/16/2026. She beneficially owns 59,802 shares held indirectly through a Roth IRA and 2,400 shares held directly in her own name.
Q/C Technologies, Inc. entered into a 12‑month consulting agreement with Chelsea Voss on January 16, 2026. She will provide services such as evaluating companies, analyzing technologies and operations, advising on potential acquisitions, and other consulting support requested by the company.
As compensation, Q/C Technologies will pay Ms. Voss $12,500 per month (or $150,000 annually) and grant her 212,500 restricted stock units that vest in four substantially equal quarterly installments, as well as stock options for up to 212,500 shares of common stock with an exercise price per share equal to the greater of $5.097 or the fair market value on the grant date, also vesting quarterly over the term.
The company also appointed Ms. Voss to its board of directors, highlighting her background in large‑scale machine learning and AI systems, including work on GPT‑4, ChatGPT, DALL·E 2, and Codex, and prior software engineering roles at several technology companies.
Q/C Technologies, Inc. (QCLS) reports Q3 2025 results showing a smaller net loss while reshaping its business. For the nine months ended September 30, 2025, the company recorded a net loss of
Total assets rose to
The capital structure is complex, with multiple preferred stock series. Mezzanine equity totaled
PharmaCyte Biotech, Inc., as a reporting person and 10% owner of Q/C Technologies, Inc. (QCLS), reported derivative equity transactions on a Form 4. On 09/04/2025, the reporting person acquired 889,865 shares of Series H Convertible Preferred Stock and related warrants, each ultimately linked to 889,865 shares of common stock. The Series H preferred is convertible into common stock at a conversion price of
Q/C Technologies, Inc. (QCLS)11,420 shares of common stock through a grant of restricted stock units at a price of $0 per share, bringing their directly held beneficial ownership to 12,500 shares. The RSUs were originally granted on 10/03/2025, subject to stockholder approval of an amendment to the company’s 2021 Equity Incentive Plan. Stockholders approved this plan amendment on 11/14/2025, and the RSUs vested immediately upon issuance.
Q/C Technologies, Inc. (QCLS) reported an equity award to a director. A board member received 22,839 shares of common stock on November 14, 2025, reported as acquired at a price of $0, bringing this person’s directly held stake to 25,024 shares after the transaction. The shares represent restricted stock units that were originally granted on October 3, 2025 under the company’s 2021 Equity Incentive Plan, subject to stockholder approval of a plan amendment. Stockholders approved that amendment on November 14, 2025, and the RSUs vested immediately upon issuance.
Q/C Technologies, Inc. (QCLS) reported an equity award to one of its directors. On November 14, 2025, the director acquired 22,839 shares of common stock at a reported price of $0, bringing the director’s beneficial ownership to 25,000 shares held directly. The filing explains that this reflects a grant of restricted stock units (RSUs) that were originally granted on October 3, 2025, subject to stockholder approval of an amendment to the company’s 2021 Equity Incentive Plan. Stockholders approved that plan amendment on November 14, 2025, and the RSUs vested immediately upon issuance on that date, resulting in the reported share ownership.
Q/C Technologies, Inc. (QCLS)November 14, 2025, the director received 25,000 shares of common stock classified as acquired at a price of $0, held as direct ownership after the transaction. According to the explanation, this reflects a grant of Restricted Stock Units (RSUs) originally awarded on October 3, 2025, which was subject to stockholder approval of an amendment to the company’s 2021 Equity Incentive Plan. Stockholders approved the plan amendment on November 14, 2025, and the RSUs vested immediately upon issuance, resulting in the director’s beneficial ownership of these 25,000 shares.